» » »

Aggressive Breast Cancer Treatments Boone NC

The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

Theodore Flint Gray III, MD
(828) 264-8004
870 State Farm Rd Ste 103B
Boone, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1987

Data Provided by:
Thomas Wendall Prewitt, MD
(828) 268-0688
838 State Farm Rd Ste 1
Boone, NC
Gender
Male
Education
Medical School: Univ Of Ms Sch Of Med, Jackson Ms 39216
Graduation Year: 1988
Hospital
Hospital: Blowing Rock Hosp, Blowing Rock, Nc
Group Practice: Blue Ridge Surgical Group

Data Provided by:
Dr.Michael Tate
(828) 324-9550
Suite 210, 401 Mulberry Street Southwest
Lenoir, NC
Gender
M
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med
Year of Graduation: 1982
Speciality
Oncologist
General Information
Hospital: Catawba Mem Hosp, Hickory, Nc
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Theodore Gray III
Watauga Medcl Ctr
Boone, NC
Associated Hospitals
Seby Jones Reg Cancer Ctr

Jason Douglas Huff, MD
(336) 716-4380
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 2000

Data Provided by:
Dr.Yvonne Mack
(828) 262-4342
182 Virginia Street
Boone, NC
Gender
F
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ
Year of Graduation: 1988
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Walter Etchells Davis, MD
(828) 262-4332
330 Deerfield Rd
Boone, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1966

Data Provided by:
Theodore Gray
(828) 264-8004
Boone, NC
Specialty
Hematology-Oncology
Associated Hospitals
Po Box 3518

Yi-Kong Keung, MD
(336) 716-5847
Dept Of Internal Medicine
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Hong Kong, Fac Of Med, Hong Kong
Graduation Year: 1985

Data Provided by:
Edward Allen LeVine
(336) 716-2255
Medical Center Blvd
Winston Salem, NC
Specialty
General Surgery, Surgical Oncology

Data Provided by:
Data Provided by:

Aggressive Breast Cancer Treatments

Provided By:

TUESDAY, Aug. 25 (HealthDay News) -- The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

However, the finding is no reason to ditch the anti-cancer drug, as even the lead researcher emphasized.

"All treatments have risks and benefits," said study author Dr. Christopher Li, an associate member of the Fred Hutchinson Cancer Research Center in Seattle. "We know that the benefits of tamoxifen treatment clearly outweigh the risks. This study adds another risk, but doesn't change the overall balance. If you consider the full balance, for most women the benefits are going to far outweigh the risks."

Li and his colleagues evaluated tamoxifen use among 1,103 breast cancer survivors from the Seattle and Puget Sound area. The women were diagnosed initially with ER-positive breast cancer, the more common and less aggressive form, between the ages of 40 and 70.

Of those women, 369 developed a second breast cancer. Nearly all of those who took the hormonal therapy after surgery or other treatment used tamoxifen for five or more years. The researchers compared those who took tamoxifen with those who did not and found the drug, which blocks estrogen (which helps tumors grow) reduced ER-positive second breast cancers but boosted the risk of ER-negative tumors, which are less common but more aggressive.

"When we looked at the different types of second cancers, tamoxifen only lowered the risk of the more common and less aggressive type of cancer, ER-positive," Li said. "It lowered that by about 60 percent. But it increases the risk of developing ER-negative, the more aggressive cancer, by fourfold."

The study is published online Aug. 25 in the journal Cancer Research.

Exactly why the tamoxifen boosts the risk of ER-negative second cancers is not known, but Li said it could be that prolonged tamoxifen use provides "a competitive advantage for the growth of ER-negative breast cancer cells."

Other experts agreed that the study is no reason to give up on tamoxifen. "The thing we have to remember is tamoxifen saves lives," said Dr. Victor Vogel, national vice president of research at the American Cancer Society.

"Even though the risk of ER-negative goes up, only with five years or more, the risk of ER-positive [second breast cancer] goes down," he said. "We shouldn't lose sight of that."

"I worry people are going to panic if they are taking this drug," said Dr. Minetta Liu, director of translational breast cancer research at the Georgetown University Medical Center, in Washington, D.C. But they should not, she said, because "it has helped a huge number of women."

More information

To learn more about tamoxifen, visit the National Cancer Institute.

Author: By Kathleen Doheny
HealthDay Reporter

SOURCES: Victor Vogel, M.D., national vice president, research, American Cancer Society, Atlanta; Christopher Li, M.D., Ph.D., associate member, Fred Hutchinson Cancer Research Center, Seattle; Minetta Liu, M.D., director, translational breast cancer research, Georgetown University Medical Center, Washington, D.C.; August 25, 2009, Cancer Research

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com